[go: up one dir, main page]

UA90718C2 - Новое применение агонистов печеночного рецептора х - Google Patents

Новое применение агонистов печеночного рецептора х

Info

Publication number
UA90718C2
UA90718C2 UAA200712465A UAA200712465A UA90718C2 UA 90718 C2 UA90718 C2 UA 90718C2 UA A200712465 A UAA200712465 A UA A200712465A UA A200712465 A UAA200712465 A UA A200712465A UA 90718 C2 UA90718 C2 UA 90718C2
Authority
UA
Ukraine
Prior art keywords
liver
receptor agonists
novel use
lxr
present
Prior art date
Application number
UAA200712465A
Other languages
English (en)
Ukrainian (uk)
Inventor
Бернадетт Юссон
Пьерр Брока
Жан-Луи Жуньен
Original Assignee
Лаборатуар Фурнье С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Фурнье С.А. filed Critical Лаборатуар Фурнье С.А.
Publication of UA90718C2 publication Critical patent/UA90718C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение касается терапевтического применения агониста печеночного рецептора X (LXR) для изготовления лекарственного средства, полезного для лечения диабета типа И.
UAA200712465A 2005-05-10 2006-05-10 Новое применение агонистов печеночного рецептора х UA90718C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67976805P 2005-05-10 2005-05-10

Publications (1)

Publication Number Publication Date
UA90718C2 true UA90718C2 (ru) 2010-05-25

Family

ID=37396918

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200712465A UA90718C2 (ru) 2005-05-10 2006-05-10 Новое применение агонистов печеночного рецептора х

Country Status (11)

Country Link
US (2) US8030335B2 (ru)
EP (1) EP1879561A2 (ru)
JP (1) JP4945555B2 (ru)
KR (1) KR20080009203A (ru)
CN (1) CN101171002B (ru)
AU (1) AU2006245717B8 (ru)
CA (1) CA2608052A1 (ru)
MX (1) MX2007014088A (ru)
RU (1) RU2417078C2 (ru)
UA (1) UA90718C2 (ru)
WO (1) WO2006120213A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031655A1 (en) * 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CN103063840A (zh) * 2011-10-18 2013-04-24 中国科学院武汉病毒研究所 一种细胞靶点肝x受体在制备治疗丙型肝炎病毒药物中的应用
KR102085057B1 (ko) 2012-07-19 2020-03-05 (주)아모레퍼시픽 간 ｘ 수용체 활성제를 포함하는 피부 미백제
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EP2759295A1 (en) 2013-01-29 2014-07-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents
CN107334756B (zh) * 2017-05-24 2019-11-15 中国人民解放军第四军医大学 Gw3965用于制备防治肾缺血再灌注损伤药物的应用
WO2020041673A1 (en) 2018-08-23 2020-02-27 President And Fellows Of Harvard College Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
US20210235733A1 (en) * 2020-02-04 2021-08-05 Memphis Meats, Inc. Characteristics of meat products

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
CA2392568A1 (en) 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
AUPR088100A0 (en) * 2000-10-19 2000-11-16 Bayly Design Associates Pty Ltd Juvenile plant holding device
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
WO2004058175A2 (en) * 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
JP2008531709A (ja) 2005-03-01 2008-08-14 ワイス シンノリン化合物および肝臓ｘ受容体調節物質としてのそれらの使用

Also Published As

Publication number Publication date
AU2006245717B2 (en) 2010-09-23
US20090118306A1 (en) 2009-05-07
US20100297761A1 (en) 2010-11-25
CN101171002B (zh) 2011-07-13
AU2006245717B8 (en) 2010-10-14
CA2608052A1 (en) 2006-11-16
RU2417078C2 (ru) 2011-04-27
WO2006120213A2 (en) 2006-11-16
AU2006245717A1 (en) 2006-11-16
JP2008540490A (ja) 2008-11-20
CN101171002A (zh) 2008-04-30
US8030335B2 (en) 2011-10-04
KR20080009203A (ko) 2008-01-25
WO2006120213A3 (en) 2007-06-28
EP1879561A2 (en) 2008-01-23
JP4945555B2 (ja) 2012-06-06
RU2007141058A (ru) 2009-06-20
MX2007014088A (es) 2008-02-07

Similar Documents

Publication Publication Date Title
MX2010004503A (es) Compuesto de oxadiazolidinediona.
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2005086860A3 (en) Methods for generating insulin-producing cells
TW200531692A (en) Aryl aniline derivatives as β2 adrenergic receptor agonists
IL183160A0 (en) Indazole-carboxamide compounds
TNSN08140A1 (ru)
UA105779C2 (ru) Агонисты рецептора gpr120 и их применение
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
MY159955A (en) Certain chemical entities, compositions and methods
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200612926A (en) Compounds and compositions as ppar modulators
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008083238A3 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2010068287A3 (en) Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TW200602330A (en) Compounds and compositions as PPAR modulators
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MXPA05014216A (es) Metodos para inhibir permeabilidad vascular y apoptosis.
WO2006052889A3 (en) Quinolinone-carboxamide compounds